openPR Logo
Press release

Synovial Sarcoma Market to Reach US$ 114.0 Million by 2034, at CAGR of 3.84% 2024-2034

06-21-2024 11:45 AM CET | Health & Medicine

Press release from: IMARC Group

Synovial Sarcoma Market to Reach US$ 114.0 Million by 2034,

Market Overview:

The synovial sarcoma market reached a value of US$ 75.3 Million in 2023 and expected  to reach US$ 114.0 Million by 2034, exhibiting a growth rate (CAGR) of 3.84% during 2024-2034.

Request for a Sample of this Report: https://www.imarcgroup.com/synovial-sarcoma-market/requestsample

Synovial Sarcoma Market Trends:

Synovial sarcoma is a rare and aggressive form of soft tissue cancer that primarily affects young adults. Despite its rarity, the market for synovial sarcoma therapies is gaining momentum due to several interconnected factors. Firstly, advances in medical research and technology have led to a deeper understanding of the molecular mechanisms underlying synovial sarcoma. This has paved the way for the development of targeted therapies, which are driving growth in the market. These therapies specifically target the genetic mutations responsible for synovial sarcoma, offering patients effective treatment options with fewer side effects.

Furthermore, an increase in the prevalence of synovial sarcoma has been noted in recent years. This can be attributed to improved diagnostic methods and a growing awareness among healthcare professionals. As a result, cases are being detected early, leading to a higher demand for treatment options. The pharmaceutical industry's focus on orphan diseases has also played a pivotal role in driving the synovial sarcoma market. Governments and regulatory bodies worldwide have introduced incentives to encourage the development of orphan drugs, which has attracted pharmaceutical companies to invest in research and development for rare diseases like synovial sarcoma. Moreover, collaborations between academic institutions, research organizations, and pharmaceutical companies have accelerated the pace of drug discovery and development. These partnerships have enabled the pooling of resources, knowledge, and expertise, leading to the rapid advancement of synovial sarcoma therapies.

Countries Covered:

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country:

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the synovial sarcoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the synovial sarcoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

This report also provides a detailed analysis of the current synovial sarcoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs:

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance

Competitive Landscape of Key Players :

The competitive landscape of the synovial sarcoma market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these Key Players:

Eli Lilly and Company
Takara Bio
Foghorn Therapeutics

Ask Analyst for Customization and Explore Full Report With TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=7518&flag=C

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Synovial Sarcoma Market to Reach US$ 114.0 Million by 2034, at CAGR of 3.84% 2024-2034 here

News-ID: 3548263 • Views:

More Releases from IMARC Group

GCC Health and Wellness Market Size, Share, Demand, Report, Forecast 2024-2032
GCC Health and Wellness Market Size, Share, Demand, Report, Forecast 2024-2032
IMARC Group, a leading market research company, has recently releases report titled "GCC Health and Wellness Market Report by Product Type (Functional Foods and Beverages, Beauty and Personal Care Products, Preventive and Personalized Medicinal Products, and Others), Functionality (Nutrition & Weight Management, Heart & Gut Health, Immunity, Bone Health, Skin Health, and Others), and Country 2024-2032". The study provides a detailed analysis of the industry, including the GCC health and
GCC Buy Now Pay Later Market Overview, Industry Growth Rate, Research Report 2024-2032
GCC Buy Now Pay Later Market Overview, Industry Growth Rate, Research Report 202 …
IMARC Group, a leading market research company, has recently releases report titled "GCC Buy Now Pay Later Market Report by Channel (Online, Point of Sale (POS)), Organization Size (Large Enterprises, Small and Medium Enterprises), End Use (Consumer Electronics, Fashion and Garment, Healthcare, Leisure and Entertainment, Retail, and Others), Purchase (Small Ticket Items (Up to US$ 300), Mid Ticket Items (US$ 300 - US$ 1000), Higher Prime Items (Above US$ 1000)),
Aluminium Wire Drawing Manufacturing Plant Project Report: Unit Operations, Raw Material and Utility Requirements
Aluminium Wire Drawing Manufacturing Plant Project Report: Unit Operations, Raw …
IMARC Group's report titled "Aluminium Wire Drawing Manufacturing Plant Project Report 2024: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue" provides a comprehensive guide for establishing an aluminium wire drawing manufacturing plant. The report covers various aspects, ranging from a broad market overview to intricate details like unit operations, raw material and utility requirements, infrastructure necessities, machinery requirements, manpower needs, packaging and transportation requirements, and more. In
Aluminum Ingots Manufacturing Plant Project Report 2024: infrastructure Necessities, Requirements and Cost
Aluminum Ingots Manufacturing Plant Project Report 2024: infrastructure Necessit …
IMARC Group's report titled "Aluminum Ingots Manufacturing Plant Project Report 2024: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue" provides a comprehensive guide for establishing an aluminum ingots manufacturing plant. The report covers various aspects, ranging from a broad market overview to intricate details like unit operations, raw material and utility requirements, infrastructure necessities, machinery requirements, manpower needs, packaging and transportation requirements, and more. In addition to

All 5 Releases


More Releases for Drug

Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June. The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug